SciELO - Scientific Electronic Library Online

SciELO - Scientific Electronic Library Online

Referencias del artículo

PATINO-GARCIA, Brenda et al. Association between polymorphisms of the androgen and vitamin D receptor genes with prostate cancer risk in a Mexican population. Rev. invest. clín. [online]. 2007, vol.59, n.1, pp. 25-31. ISSN 0034-8376.

    1. Dirección General de Epidemiología. Registro Histopatológico de Neoplasias Malignas, CD ©2004. www.dgepi.salud.gob.mx [ Links ]

    2. Hsing AW, Chokkalingam AP. Prostate cancer epidemiology. Front Biosci 2006: 1(11): 1388–413. [ Links ]

    3. Ko YJ, Devi GR, London CA, Kayas A, Reddy MT, et al. Androgen receptor down–regulation in prostate cancer with phosphorodiamidate morpholino antisense. J Urol 2004; 172(3): 1140–4. [ Links ]

    4. Suzuki H, Shimbo M, Ichikawa T. New biomarkers for prostate cancer. Nippon Rinsho 2005; 63(2): 351–9. [ Links ]

    5. Hakimi JM, Schoenberg MP, Rondinelli RH, Piantadosi S, Barrack ER. Androgen receptor variants with short glutamine and glycine repeats may identify unique subpopulations of men with prostate cancer. Clin Cancer Res 1997; 3: 1599–608. [ Links ]

    6. Hsing AW, Gao YT, Wu G, Wang X, Deng J, et al. Polymorphic CAG and GGN repeat lengths in the androgen receptor gene and prostate cancer risk: a population–based case–control study in China. Cancer Res 2000; 60: 5111–116. [ Links ]

    7. Mowszowicz I, Mestaver C. Mutations of the androgen receptor gene a possible role in prostate cancer. Bull Cancer 1997; 84(2): 183–8. [ Links ]

    8. Lange EM, Chen H, Brierley K, Livermore H, Wojno KJ, et al. The polymorphic exon 1 androgen receptor CAG repeat in men with a potential inherited prediposition to prostate cancer. Cancer Epidemiol Biomarkers Prev 2000; 9: 439–42. [ Links ]

    9. Correa–Cerro L, Wohr G, Haussler J, Berthon P, Drelon E, et al. (CAG)nCAA and GGN repeats in the human androgen receptor gene are not associated with prostate cancer in French–German population. Eur J Hum Genet 1999; 7: 357–62. [ Links ]

    10. Tayeb MT, Clark C, Haites NE, Sharp L, Murray GI, et al. Vitamin D receptor, HER–2 polymorphisms and risk of prostate cancer in men with benign prostate hyperplasia. Saudi Med J 2004; 25(4): 447–51. [ Links ]

    11. Bid HK, Mishra DK, Mittal RD. Vitamind–D receptor (VDR) gene (Fok–1, Taq–1 and Apa–1) polymorphisms in healthy individuals from north indian population. Asian Pac J Cancer Prev 2005; 6(2): 147–52. [ Links ]

    12. Cheteri MB, Stanford JL, Friederichsen DM, Peters MA, Iwasaki L, et al. Vitamin D receptor gene polymorphisms and prostate cancer risk. Prostate 2004; 59(4): 409–18. [ Links ]

    13. Correa–Cerro L, Berthon P, Haussler J, Bochum S, Drelon E, et al. Vitamin D receptor polymorphisms as markers in prostate cancer. Hum Genet 1999; 105: 281–7. [ Links ]

    14. Ntais C, Polycarpou A, Ioannidis JP. Vitamin D receptor gene polymorphisms and risk of prostate cancer: a meta–analysis. Cancer Epidemiol Biomarkers Prev 2003; 12(12): 1395–402, . [ Links ]

    15. Macoska J. Ancestry, genetic susceptibility, E/Caqdherin160A and prostate cancer risk– is there an association? J Urol 2006; 176(2): 435–6. [ Links ]

    16. Chamberlain NL, Driver ED, Miesfeld RL. The length and location of CAG trinucleotide repeats in the androgen receptor N–terminal domain affect transactivation function. Nucleic Acids Res 1994; 2: 3181–6. [ Links ]

    17. Coetzee GA, Ross RK. Re: Prostate cancer and the androgen receptor. J Nati Cancer Inst 1994; 86: 872–3. [ Links ]

    18. Irvine RA, Ma H, Yu MC, Ross RK, Stallcup MR, et al. Inhibition of p160–mediated coactivation with increasing androgen receptor polyglutamine length. Hum Mol Genet 2000; 9: 267–74. [ Links ]

    19. Nelson KA, Witte JS. Androgen receptor CAG repeats and prostate cancer. Am J Epidemiol 2002; 155: 883–90. [ Links ]

    20. Yoshida KI, Yano M, Chiba K, Honda M, Kitahara S. CAG repeat length in the androgen receptor gene is enhanced in patients with idiopathic azoospermia. Urology 1999; 54: 1078–81. [ Links ]

    21. Zitzmann M, Brune M, Kornmann B, Gromoll J, Junker R, et al. The CAG repeat polymorphism in the androgen receptor gene affects bone density and bone metabolism in healthy males. Clin Endocrinol (Oxf) 2001; 55: 649–57. [ Links ]

    22. Sawaya ME, Shalita AR. Androgen receptor polymorphisms (CAG repeat lengths) in androgenetic alopecia, hirsutism, and acne. J Cutan Med Surg 1998; 3: 9–15. [ Links ]

    23. Giovannucci E, Stampfer MJ, Chan A, Krithivas K, Gann PH, et al. CAG repeat within the androgen receptor gene and incidence of surgery for benign prostatic hyperplasia in U.S. physicians. Prostate 1999; 39: 130–4. [ Links ]

    24. Giovannucci E, Platz EA, Stampfer MJ, Chan A, Krithivas K, et al. The CAG repeat within the androgen receptor gene and benign prostatic hyperplasia. Urology 1999; 53: 121–5. [ Links ]

    25. Mitsumori K, Terai A, Oka H, Segawa T, Ogura K, et al. Androgen receptor CAG repeat length polymorphism in benign prostatic hyperplasia (BPH): correlation with adenoma growth. Prostate 1994; 41: 253–57. [ Links ]

    26. Shibata A, Stamey TA, McNeal JE, Cheng I, Peehl DM. Genetic polymorphisms in the androgen receptor and type II 5a–reductase genes in prostate enlargement. J Urol 2001; 166: 1560–4. [ Links ]

    27. Bousema JT, Bussemakers MJ, van Houwelingen KP, Debruyne FM, Verbeek AL, et al. Polymorphisms in the vitamin D receptor gene and the androgen receptor gene and the risk of benign prostatic hyperplasia. Eur Urol 2000; 37: 234–8. [ Links ]

    28.  Roberts RO, Bergstralh EJ, Cunningham JM, Hebbring SJ, Thibodeau SN, et al. Androgen receptor gene polymorphisms and increased risk of urologic measures of benign prostatic hyperplasia. Am J Epidemiol 2004; 159(3): 269–76. [ Links ]

    29. Xue W, Irvine RA, Yu MC, Ross RK, Coetze GA, et al. Susceptibility to prostate cancer: interaction beetwen genotypes at the androgen receptor and prostate–specific antigen loci. Cancer Res 2000; 60: 839–41. [ Links ]

    30. Gastón KE, Kim D, Singh S, Ford H, Mohler JL. Racial differences in androgen receptor protein expression in men with clinically localized prostate cancer. J Urol 2003; 170; 990–3. [ Links ]

    31. Yu H, Bharaj B, Vassilikos EJ, Giai M, Diamandis EP. Shorter CAG repeat length in the androgen receptor gene is associated with more agressive forms of breast cancer. Breast Cancer Res Treat 2000; 59: 153–61. [ Links ]

    32. Visvanathan K, Helzlsouer KJ, Boorman DW, Strickland PT, Hoffman SC, et al. Association among an ornithine decar–boxylase polymorphism, androgen receptor gene (CAG) repeat length and prostate cancer risk. J Urol 2004; 171(2): 652–5. [ Links ]

    33.  Balic I, Graham ST, Troyer DA, Higgins BA, Pollock BH, et al. Androgen receptor length polymorphism associated with prostate cancer risk in hispanic men. J Urol 2002; 168(5): 2245–8. [ Links ]

    34. Zhao XY, Peehl DM, Navone NM, Feldman D. 1 alpha, 25–dihydroxyvitamin D3 inhibits prostate cancer cell growth by androgen–dependent and androgen–independent mechanisms. Endocrinology 2000; 141: 2548–56. [ Links ]

    35. Price DK, Franks ME, Figg WD. Genetic variations in the vitamin D receptor, androgen receptor and enzymes that regulate androgen metabolism. J Urol 2004; 171(2 Suppl.): 45–9. [ Links ]

    36. Gsur A, Madersbacher S, Haidinger G, Schatzl G, Marberger M, et al. Vitamin D receptor gene polymorphism and prostate cancer risk. Prostate 2002: 51(1): 30–4. [ Links ]

    37. Paiss T, Gschwend J, Autenrieth M, Correa–Cerro L, Haussler J, et al. Vitamin D receptor polymorphisms and prostate cancer risk in an European population. J Urol 1999; 161 (4S): 56. [ Links ]